Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
2.480
+0.185 (8.06%)
At close: Mar 9, 2026, 4:00 PM EDT
2.490
+0.010 (0.40%)
After-hours: Mar 9, 2026, 5:56 PM EDT
Zentalis Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 161 | 216 | 1,072 | 1,149 | 3,808 | 2,109 | |
| Market Cap Growth | -2.88% | -79.86% | -6.72% | -69.82% | 80.54% | - | |
| Enterprise Value | -80 | -132 | 601 | 775 | 3,443 | 1,769 | |
| Last Close Price | 2.48 | 3.03 | 15.15 | 20.14 | 84.06 | 51.94 | |
| PS Ratio | 5.98 | 3.20 | - | - | - | - | |
| PB Ratio | 0.71 | 0.64 | 2.45 | 2.65 | 10.45 | 6.33 | |
| P/TBV Ratio | 0.64 | 0.64 | 2.47 | 2.67 | 10.57 | 7.13 | |
| Debt / Equity Ratio | 0.16 | 0.13 | 0.11 | 0.11 | 0.13 | 0.01 | |
| Net Debt / Equity Ratio | -0.95 | -0.97 | -1.00 | -0.90 | -0.81 | -1.01 | |
| Net Debt / EBITDA Ratio | 1.58 | 1.76 | 1.77 | 1.73 | 1.42 | 2.84 | |
| Net Debt / FCF Ratio | 1.79 | 1.92 | 2.10 | 2.35 | 1.84 | 3.84 | |
| Asset Turnover | 0.07 | 0.14 | - | - | - | - | |
| Quick Ratio | 7.55 | 7.13 | 6.96 | 7.72 | 7.74 | 11.85 | |
| Current Ratio | 7.76 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | |
| Return on Equity (ROE) | -49.18% | -42.83% | -67.09% | -59.39% | -47.60% | -59.01% | |
| Return on Assets (ROA) | -24.51% | -23.86% | -28.53% | -28.59% | -31.67% | -32.77% | |
| Return on Capital Employed (ROCE) | -52.60% | -49.60% | -51.60% | -47.10% | -50.60% | -35.30% | |
| Earnings Yield | -92.98% | -76.80% | -27.25% | -20.60% | -4.17% | -5.59% | |
| FCF Yield | -83.45% | -79.23% | -19.44% | -14.47% | -4.21% | -4.15% | |
| Buyback Yield / Dilution | -1.13% | -8.67% | -23.75% | -23.82% | -51.84% | -402.29% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.